Establishment of the 2nd WHO IS for anti-SARS-CoV-2
Report Download the ReportEnquiries Connect with our team of dedicated scientists
The merger of Cerba Research and Viroclinics-DDL
After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the group’s global clinical trial central and speciality laboratory services division, has now merged with Viroclinics-DDL, a fast-growing global specialist virology and immunology contract research organisation (CRO).
Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO), from Summit Partners.
Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network
Today, Viroclinics-DDL, a global Contract Research Organization supporting clinical and preclinical studies for drug and vaccine development and CEPI, the Coalition for Epidemic Preparedness Innovations, signed an agreement which allows Viroclinics-DDL to produce and distribute laboratory stocks of the Omicron SARS-CoV-2 variant for use in CEPI’s centralised COVID-19 vaccine testing network. The produced Omicron SARS-COV-2 variant will be used for the performance of laboratory assays, assessing the neutralizing potential of COVID-19 vaccines against the new variant.
Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant).
Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies,
today announced new results on the efficacy of Atriva’s lead candidate zapnometinib against coronaviruses.
Launching our new business unit Viroclinics Xellerate
Viroclinics-DDL, today announced the launch of Viroclinics Xellerate, a newly formed Business Unit focused on clinical trial support and global logistics services.
Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its PARP inhibitor, stenoparib, against Coronavirus variant B.1.1.7 (British variant). The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.
Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses
Sabin-strain oral polio vaccines (OPV) can, in rare instances, cause disease in recipients and susceptible contacts or evolve to
become circulating vaccine-derived strains with the potential to cause outbreaks.
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
Article Open the article hereEnquiries Connect with our team of dedicated scientists